Dark

RMD
ResMed Inc.
stock NYSE

At Close

Jul 24, 2026 3:59:54 PM EDT

195.29USD+1.772%(+3.40)1,005,233

0.00Bid 0.00Ask 0.00Spread

Pre-market

0.00USD-100.000%(-191.89)0

After-hours

Jul 24, 2026 4:00:30 PM EDT

195.27USD-0.010%(-0.02)214,449

OverviewOptionsHistoricalExchangesShortsNews

Jan 31, 2022

02:26PM EST Expert Ratings For ResMed Benzinga

01:01PM EST Citigroup Upgrades ResMed to Buy Benzinga

Jan 28, 2022

12:33PM EST EXCLUSIVE: ResMed CEO, Mick Farrell Now Interviewing On Benzinga's Live YouTube TV Benzinga

10:36AM EST EXCLUSIVE: ResMed CEO, Mick Farrell To Appear On Benzinga's Live YouTube TV At 12:30 p.m. ET On Friday Benzinga

10:17AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 28, 2022 Benzinga

09:51AM EST ResMed's Return on Invested Capital Overview Benzinga

08:21AM EST The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron Benzinga

06:33AM EST ResMed Q2 Earnings Highlights: Supply Chain Constraints, Unlimited Demand Due To Competitor Recall Benzinga

05:09AM EST RBC Capital Upgrades ResMed to Sector Perform, Announces $241 Price Target Benzinga

Jan 27, 2022

04:45PM EST Recap: ResMed Q2 Earnings Benzinga

04:39PM EST ResMed Q2 EPS $1.37 Vs. $1.23 Year Ago RTTNews

04:35PM EST Resmed Inc (RMD) Declares Quarterly Dividend of $ 0.42, Record Date 2/10/2022 RTTNews

04:35PM EST Resmed Inc (RMD) reported earnings for second quarter that missed the Street estimates. RTTNews

04:15PM EST ResMed Q2 Adj. EPS $1.47 Misses $1.52 Estimate, Sales $894.90M Miss $935.25M Estimate Benzinga

07:58AM EST The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study Benzinga

04:37AM EST Earnings Scheduled For January 27, 2022 Benzinga

Jan 26, 2022

10:51AM EST Earnings Preview: ResMed Benzinga

Jan 24, 2022

03:28PM EST JP Morgan Upgrades ResMed to Overweight, Raises Price Target to $270 Benzinga

01:39PM EST Hearing JP Morgan Upgraded ResMed To Overweight Benzinga

10:05AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 24, 2022 Benzinga

07:07AM EST B of A Securities Upgrades ResMed to Neutral Benzinga

Jan 23, 2022

11:03AM EST The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More Benzinga

Jan 13, 2022

12:02PM EST What 4 Analyst Ratings Have To Say About ResMed Benzinga

11:50AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 13, 2022 Benzinga

11:47AM EST Baird Upgrades ResMed to Outperform, Raises Price Target to $300 Benzinga

11:45AM EST RBC Capital Maintains Underperform on ResMed, Raises Price Target to $234 Benzinga

11:44AM EST CLSA Upgrades ResMed to Buy Benzinga

Jan 6, 2022

04:05PM EST ResMed to Report Second Quarter Fiscal 2022 Earnings on January GlobeNewswire Inc

Jan 3, 2022

09:00AM EST ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, beginning at approximately 1:30 p.m. (Eastern Standard Time) via webcast. GlobeNewswire Inc

Dec 30, 2021

09:00AM EST ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will present at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference on Thursday, January 6, 2022, beginning at approximately 4:00 p.m. (Eastern Standard Time). GlobeNewswire Inc

Dec 21, 2021

10:14AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2021 Benzinga

04:32AM EST Keybanc Upgrades ResMed to Overweight, Announces $302 Price Target Benzinga

Dec 6, 2021

10:05AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2021 Benzinga

06:45AM EST Macquarie Upgrades ResMed to Outperform Benzinga

Nov 19, 2021

09:00AM EST -- Tan is vice president and managing director of Microsofts Health and Life Science R&D -- Hernandez is Googles head of clinical research, health economics, and outcomes research -- Both leaders digital health experience at world-leading tech firms can help oversee ResMeds strategy to improve 250 million lives in 2025 -- ResMeds board increases from eight to ten directors GlobeNewswire Inc

Nov 3, 2021

09:00AM EDT ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will participate in a virtual fireside chat at the Credit Suisse 30th Annual Healthcare Conference on Wednesday, November 10, 2021, beginning at approximately 1:00 p.m. (Eastern Standard Time) via video webcast. GlobeNewswire Inc

Oct 29, 2021

09:47AM EDT RBC Capital Maintains Underperform on ResMed, Lowers Price Target to $227 Benzinga

08:00AM EDT The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs Benzinga

Oct 28, 2021

05:04PM EDT Resmed Inc (RMD) revealed earnings for its first quarter that rose from the same period last year. RTTNews

05:02PM EDT ResMed Q1 EPS $1.39 Vs. $1.22 Year Ago RTTNews

04:33PM EDT ResMed Q1 EPS $1.51 Beats $1.36 Estimate, Sales $904.00M Beat $866.33M Estimate Benzinga

08:30AM EDT Integra LifeSciences Announces Jan De Witte as President and Chief GlobeNewswire Inc

08:26AM EDT The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug Benzinga

04:08AM EDT Earnings Scheduled For October 28, 2021 Benzinga

Oct 24, 2021

11:45AM EDT The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More Benzinga

Oct 7, 2021

04:05PM EDT ResMed to Report First Quarter Fiscal 2022 Earnings on October 28, GlobeNewswire Inc

Sep 10, 2021

08:00AM EDT The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test Benzinga

Sep 9, 2021

08:17AM EDT The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization Benzinga

Sep 8, 2021

09:00AM EDT ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will participate in a virtual fireside chat at the Bank of America Global Healthcare Conference on Wednesday, September 15, 2021, beginning at approximately 5:35 p.m. (British Summer Time) via video webcast. GlobeNewswire Inc

07:32AM EDT The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod Benzinga

06:45AM EDT Using PAP (positive airway pressure) therapy as directed can significantly increase sleep apnea patients chances of living longer, according to a late-breaking abstract presented today at the virtual European Respiratory Society (ERS) International Congress 2021 and supported by ResMed (NYSE: RMD, ASX: RMD). GlobeNewswire Inc

Sep 2, 2021

09:00AM EDT ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Thursday, September 9, 2021, beginning at approximately 1:15 p.m. (Eastern Daylight Time) via video webcast. GlobeNewswire Inc

Aug 31, 2021

08:15AM EDT The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical Benzinga

Aug 25, 2021

04:15PM EDT ResMed (NYSE: RMD, ASX: RMD), today announced the promotion of Bobby Ghoshal to President of ResMeds SaaS business, effective immediately. Raj Sodhi will be leaving full-time employment at ResMed, effective September 1. GlobeNewswire Inc

09:03AM EDT Supermoon Capital Launches with World's First Fund Focused on Sleep PR Newswire

Aug 24, 2021

08:09AM EDT The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal Benzinga

Aug 20, 2021

07:45AM EDT The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data Benzinga

Aug 19, 2021

10:57AM EDT The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck Benzinga

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 16, 2021

03:54PM EDT Suffers' Lose Sleep After Philips' Recall Of Sleep Apnea Machine: WSJ Benzinga

09:00AM EDT ResMed, a global leader in digital health and sleep apnea treatment, (NYSE: RMD, ASX: RMD) today launched AirSense 11, available first in the U.S., the companys next-generation PAP (positive airway pressure) device designed to help hundreds of millions of people worldwide with sleep apnea1 start and stay on therapy to treat and manage obstructive sleep apnea. GlobeNewswire Inc

Aug 5, 2021

05:33PM EDT ResMed Q4 EPS $1.35 Beats $1.28 Estimate, Sales $876.10M Beat $783.18M Estimate Benzinga

04:52PM EDT ResMed Q4 EPS $1.33 Vs. $1.22 Year Ago RTTNews

04:48PM EDT Resmed Inc (RMD) released a profit for its fourth quarter that rose from last year. RTTNews

04:46PM EDT Resmed Inc (RMD) Declares Quarterly Dividend of $ 0.42, Record Date 8/19/2021 RTTNews

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

Aug 4, 2021

07:52AM EDT The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings Benzinga

Aug 2, 2021

01:20PM EDT Where ResMed Stands With Analysts Benzinga

01:17PM EDT Expert Ratings for ResMed Benzinga

11:45AM EDT CLSA Downgrades ResMed to Sell Benzinga

10:23AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2021 Benzinga

06:14AM EDT Needham Downgrades ResMed to Hold Benzinga

Jul 30, 2021

07:54AM EDT The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs Benzinga

Jul 29, 2021

12:03PM EDT Expert Ratings For ResMed Benzinga

08:18AM EDT The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs Benzinga

Jul 28, 2021

10:23AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2021 Benzinga

07:45AM EDT 10 Biggest Price Target Changes For Wednesday Benzinga

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

05:13AM EDT Jefferies Upgrades ResMed to Hold, Raises Price Target to $240 Benzinga

Jul 27, 2021

11:13AM EDT RBC Capital Maintains Underperform on ResMed, Raises Price Target to $238 Benzinga

Jul 26, 2021

10:42AM EDT JP Morgan Downgrades ResMed to Neutral, Raises Price Target to $246 Benzinga

Jul 23, 2021

07:45AM EDT The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs Benzinga

Jul 15, 2021

04:05PM EDT ResMed to Report Fourth Quarter Fiscal 2021 Earnings on August 5, 2021 GlobeNewswire Inc

Jul 14, 2021

10:04AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2021 Benzinga

04:57AM EDT RBC Capital Initiates Coverage On ResMed with Underperform Rating, Announces Price Target of $223 Benzinga

Jul 8, 2021

07:45AM EDT The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test Benzinga

Jul 2, 2021

07:38AM EDT The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures Benzinga

Jun 30, 2021

07:29AM EDT The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs Benzinga

Jun 25, 2021

07:32AM EDT The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs Benzinga

Jun 24, 2021

08:12AM EDT The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO Benzinga

Jun 22, 2021

11:50AM EDT Expert Ratings For ResMed Benzinga

06:01AM EDT Baird Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $240 Benzinga

Jun 21, 2021

07:53AM EDT 10 Biggest Price Target Changes For Monday Benzinga

05:28AM EDT Needham Maintains Buy on ResMed, Raises Price Target to $267 Benzinga

Jun 16, 2021

01:16PM EDT 5 Reasons Why ResMed Gets Downgrade From BofA Securities Benzinga

10:06AM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2021 Benzinga

08:40AM EDT B of A Securities Downgrades ResMed to Underperform, Raises Price Target to $221 Benzinga

08:20AM EDT The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO Benzinga

Jun 15, 2021

11:15AM EDT P/E Ratio Insights for ResMed Benzinga

10:10AM EDT 10 Biggest Price Target Changes For Tuesday Benzinga

08:07AM EDT The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda Benzinga

07:54AM EDT Oppenheimer Maintains Outperform on ResMed, Raises Price Target to $270 Benzinga

Jun 2, 2021

09:00AM EDT ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021, beginning at approximately 1:20 p.m. (Eastern Daylight Time) via video webcast. GlobeNewswire Inc

May 25, 2021

04:05PM EDT ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will participate in a virtual fireside chat at the William Blair 41st Annual Growth Stock Conference on Tuesday, June 1, 2021, beginning at approximately 1:20 p.m. (Central Daylight Time) via video webcast. GlobeNewswire Inc

May 21, 2021

10:08AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 21, 2021 Benzinga

09:04AM EDT JP Morgan Upgrades ResMed to Overweight, Raises Price Target to $219 Benzinga

May 11, 2021

10:07AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2021 Benzinga

08:04AM EDT Citigroup Upgrades ResMed to Buy Benzinga

May 3, 2021

05:09PM EDT Bone Health Technologies Raises $2.5M In New Funding Round, Adds 3 Members To Board Benzinga

10:03AM EDT Bone Health Technologies, a leading innovator of technologies for improving bone health, announces today the close of its $2.5 million funding round and the appointment of three board members: Karen Drexler, MBA, Nancy Lynch, MD, MBA and Sam Goldberger, MD, MBA. GlobeNewswire Inc

Apr 30, 2021

11:23AM EDT ResMed Shares Move Lower; Hearing Citi Downgrades From Buy To Neutral Benzinga

11:08AM EDT ResMed Inc. (RMD) shares are declining on Friday morning trade as the company slipped to loss in the third quarter. The company attributed the loss to an additional income tax reserve of $254.8 million. RTTNews

12:59AM EDT ResMed Inc. (RMD, RMD.AX) reported that its third-quarter net loss was $78.48 million or $0.54 per share compared to net income of $163.14 million or $1.12 per share in the prior year. The loss was predominantly due to the additional income tax reserve of $254.8 million. RTTNews

Apr 29, 2021

04:53PM EDT ResMed Q3 Loss/share $0.54 Vs. Profit $1.12 Year Ago RTTNews

04:47PM EDT ResMed Q3 EPS $1.30 Beats $1.28 Estimate, Sales $768.80M Miss $801.83M Estimate Benzinga

08:15AM EDT The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx Benzinga

04:10AM EDT Earnings Scheduled For April 29, 2021 Benzinga

Apr 28, 2021

10:47AM EDT ResMed Earnings Preview Benzinga

Apr 27, 2021

09:00AM EDT ResMed (NYSE: RMD, ASX: RMD) today announced Brett Sandercock, chief financial officer, will present virtually at the Macquarie Australia Conference on Wednesday, May 5, 2021, beginning at approximately 8:45 a.m. (Australian Eastern Standard Time) via video webcast. GlobeNewswire Inc

Apr 24, 2021

09:24AM EDT The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx Benzinga

Apr 8, 2021

04:05PM EDT ResMed to Report Third Quarter Fiscal 2021 Earnings on April 29, 2021 GlobeNewswire Inc

Mar 16, 2021

10:38AM EDT Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2021 Benzinga

09:00AM EDT ResMed Announces Participation in KeyBanc's Capital Markets' Life Sciences & MedTech Investor Forum Business Wire

06:51AM EDT Needham Upgrades ResMed to Buy, Announces $229 Price Target Benzinga

Mar 15, 2021

07:30AM EDT Tactile Medical Appoints Kristie Burns as Senior Vice President of GlobeNewswire Inc

Jan 28, 2021

05:15PM EST Recap: ResMed Q2 Earnings Benzinga

04:18PM EST ResMed Q2 EPS $1.41 Beats $1.26 Estimate, Sales $800.00M Beat $783.18M Estimate Benzinga

04:14PM EST Resmed Inc (RMD) announced a profit for its second quarter that climbed from last year. RTTNews

04:12PM EST Resmed Inc (RMD) Declares Quarterly Dividend of $ 0.39, Record Date 2/11/2021 RTTNews

04:08PM EST ResMed Q2 EPS $1.23 Vs. $1.10 Year Ago RTTNews

04:05PM EST ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2021 Business Wire

08:03AM EST The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO Benzinga

04:08AM EST Earnings Scheduled For January 28, 2021 Benzinga

Jan 27, 2021

10:15AM EST ResMed's Earnings Outlook Benzinga

Jan 23, 2021

09:14AM EST The Week Ahead In Biotech (Jan 24-30): J&J, Lilly to Kickstart Big Pharma Earnings, Amgen FDA Decision and More Benzinga

Jan 7, 2021

04:05PM EST ResMed to Report Second Quarter Fiscal 2021 Earnings on January 28, 2021 Business Wire

Jan 5, 2021

09:00AM EST ResMed Announces Participation in the 39th Annual J.P. Morgan Healthcare Conference Business Wire

Dec 16, 2020

01:20PM EST 'Halftime Report' Final Trades: Home Depot, Tractor Supply And More Benzinga

Nov 10, 2020

08:40AM EST The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies Benzinga

Nov 6, 2020

02:47PM EST Stocks Trading Near 52-Week Highs On Friday, Nov. 6, 2020: SID, SE, TEKKU, PFXI, HERO, MORN, RMD, ROL, FSV, TMO, KBLMR, STNE, DWLD, BFT, JSML, BRKS, FORM, EBIZ, MAACU, QQEW, LBRDK, POOL, LBRDA, GLIBA, CHN, DCRBU, SMMCW, MELI, SITE Benzinga

07:47AM EST The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold Benzinga

Nov 5, 2020

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

Nov 3, 2020

09:00AM EST ResMed Announces Participation in the Credit Suisse 29th Annual Global Healthcare Conference Business Wire

Oct 30, 2020

08:09AM EDT The Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinson's Study, 2 Biotechs Make Wall Street Debuts Benzinga

Oct 29, 2020

04:48PM EDT ResMed Q1 Adj. EPS $1.27 Beats $0.99 Estimate, Sales $751.90M Beat $699.03M Estimate Benzinga

04:33PM EDT Resmed Inc (RMD) reported a profit for its first quarter that increased from the same period last year. RTTNews

04:32PM EDT ResMed Q1 EPS $1.22 Vs. $0.83 Year Ago RTTNews

04:06PM EDT ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2021 Business Wire

07:30AM EDT The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal Benzinga

04:08AM EDT Earnings Scheduled For October 29, 2020 Benzinga

Oct 8, 2020

04:05PM EDT ResMed to Report First Quarter Fiscal 2021 Earnings on October 29, 2020 Business Wire

Sep 9, 2020

09:00AM EDT ResMed Announces Participation in the Morgan Stanley 18th Annual Global Healthcare Conference Business Wire

Sep 1, 2020

09:16AM EDT ResMed Debuts AirTouch N20 Foam CPAP Mask, Its 'Softest Nasal Mask Ever' Benzinga

Aug 26, 2020

08:04AM EDT Propeller Health Reports Co Enters Japan With Digital Health Sensor For New Enerzair, Atectura Breezhaler Asthma Medications Benzinga

Aug 11, 2020

10:01AM EDT VIDA appoints digital health technology leader Karen Drexler to board of PR Newswire

Aug 6, 2020

09:43AM EDT Hearing ResMed Shares Downgraded To Neutral By Goldman Sachs Benzinga

Aug 5, 2020

05:04PM EDT ResMed Q4 Adj. EPS $1.33 Beats $1.08 Estimate, Sales $770.30M Beat $746.90M Estimate Benzinga

04:13PM EDT Resmed Inc (RMD) revealed a profit for its fourth quarter that rose from the same period last year. RTTNews

04:11PM EDT ResMed Q4 GAAP EPS $1.22; Non-GAAP EPS $1.33 RTTNews

04:06PM EDT ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2020 Business Wire

04:21AM EDT Earnings Scheduled For August 5, 2020 Benzinga

Jul 15, 2020

04:30PM EDT ResMed to Report Fourth Quarter Fiscal 2020 Earnings on August 5, 2020 Business Wire

document.getElementById("ZW1Ynl").onerror = function(){this.style.display='none';}; .dark-mode .GTvDl2{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .GTvDl2{ color: #333333; background-color: white; border: 2px solid #333333; }RMDResMed Inc.stock NYSE

RMD
ResMed Inc.
stock NYSE